La Jolla Pharmaceutical Company to Present at the Rodman & Renshaw Annual Global Investment Conference on September 9, 2013
(firmenpresse) - SAN DIEGO, CA -- (Marketwired) -- 09/05/13 -- (OTCBB: LJPC) (the "Company" or "La Jolla"), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that the Company will present at the Rodman & Renshaw Global Investment Conference. George F. Tidmarsh, MD, PhD, President and Chief Executive Officer of La Jolla will present at 4:30 pm Eastern Time on Monday, September 9th. The conference will be held in the Millennium Broadway Hotel in New York City.
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501 is a product candidate for the treatment of hepatorenal syndrome. For more information on the Company please visit .
This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operations. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause actual results to be materially different from these forward-looking statements. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company's filings with the U.S. Securities and Exchange Commission ("SEC"), all of which are available free of charge on the SEC's web site . These risks include, but are not limited to, risks relating to the development of GCS-100 and LJPC-501, the success and timing of future preclinical and clinical studies of these compounds, and potential indications for which GCS-100 and LJPC-501 may be developed. Subsequent written and oral forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in the Company's reports filed with the SEC. The Company expressly disclaims any intent to update any forward-looking statements.
George F. Tidmarsh, M.D., Ph.D.
President & Chief Executive Officer
La Jolla Pharmaceutical Company
Phone: (858) 207-4264
Email:
Chester S. Zygmont, III
Director of Finance
La Jolla Pharmaceutical Company
Phone: (858) 207-4262
Email:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 05.09.2013 - 06:00 Uhr
Sprache: Deutsch
News-ID 1260736
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SAN DIEGO, CA
Phone:
Kategorie:
Equipment & Supplies
Anmerkungen:
Diese Pressemitteilung wurde bisher 169 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"La Jolla Pharmaceutical Company to Present at the Rodman & Renshaw Annual Global Investment Conference on September 9, 2013
"
steht unter der journalistisch-redaktionellen Verantwortung von
La Jolla Pharmaceutical Company (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
